title: The Prognostic Value of High-Sensitive Troponin I in Stable Coronary Artery Disease Depends on Age and Other Clinical Variables.
abstract: OBJECTIVE
  To study the prognostic value of high-sensitive troponin (hs-cTn) I in stable coronary artery disease.
  
  
  METHODS
  In total, we studied 705 patients. Secondary outcomes were the incidence of: (1) acute ischemic events and (2) heart failure or death. The primary outcome was the composite of them.
  
  
  RESULTS
  Patients with hs-cTnI >0 ng/ml (62.1%) were older, had a lower estimated glomerular filtration rate, more frequent a history of hypertension, atrial fibrillation, ejection fraction <40%, and therapy with angiotensin-converting enzyme inhibitors, diuretics and acenocumarol. The follow-up period was 2.2 ± 0.99 years. Fifty-three patients suffered an acute ischemic event, 33 died or suffered heart failure and 78 developed the primary outcome. By univariate Cox's regression analysis, hs-cTnI >0 was associated with a higher risk of developing the primary outcome [relative risk = 2.360 (1.359-4.099); p = 0.001] and heart failure or death [relative risk = 5.932 (1.806-19.482); p < 0.001], but not with acute ischemic events. Statistical significance was lost after controlling for age. By logistic regression analysis, age [relative risk = 1.026 (1.009-1.044); p = 0.003], ejection fraction <40% [relative risk = 4.099 (2.043-8.224); p < 0.001], use of anticoagulants [relative risk = 2.785 (1.049-7.395); p = 0.040] and therapy with angiotensin-converting enzyme inhibitors [relative risk = 1.471 (1.064-2.034); p = 0.020], and estimated glomerular filtration rate [relative risk = 0.988 (0.977-0.999); p = 0.027] were associated with hs-cTnI >0.
  
  
  CONCLUSIONS
  In stable coronary disease, hs-cTnI is associated with the incidence of heart failure or death, but this relationship depends on other variables.
authors.affiliation: Department of Cardiology, Hospital de Fuenlabrada, Madrid, Spain.
authors.forename: Rocío
authors.initials: R
authors.lastname: Carda
authors.forename: Álvaro
authors.initials: Á
authors.lastname: Aceña
authors.forename: Ana
authors.initials: A
authors.lastname: Pello
authors.forename: Carmen
authors.initials: C
authors.lastname: Cristóbal
authors.forename: Nieves
authors.initials: N
authors.lastname: Tarín
authors.forename: Ana
authors.initials: A
authors.lastname: Huelmos
authors.forename: Joaquín
authors.initials: J
authors.lastname: Alonso
authors.forename: Dolores
authors.initials: D
authors.lastname: Asensio
authors.forename: Óscar
authors.initials: Ó
authors.lastname: Lorenzo
authors.forename: José Luis
authors.initials: JL
authors.lastname: Martín-Ventura
authors.forename: Luis
authors.initials: L
authors.lastname: Blanco-Colio
authors.forename: Jerónimo
authors.initials: J
authors.lastname: Farré
authors.forename: Lorenzo
authors.initials: L
authors.lastname: López Bescós
authors.forename: Jesús
authors.initials: J
authors.lastname: Egido
authors.forename: José
authors.initials: J
authors.lastname: Tuñón
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D015415:Biomarkers; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000401:mortality*; D005260:Female; D005919:Glomerular Filtration Rate; D006333:Heart Failure / Q000453:epidemiology*; D006801:Humans; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D012307:Risk Factors; D019210:Troponin I / Q000097:blood*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000925:Anticoagulants; D015415:Biomarkers; D019210:Troponin I